Eckert & Ziegler Purchases Manufacturer of X-Ray Devices. Eckert & Ziegler Strahlen- und Medizintechnik AG, DE0005659700
Berlin, 19 December 2017 - Eckert & Ziegler BEBIG GmbH signed an agreement to acquire Thuringia (Germany)-based WOLF-Medizintechnik GmbH (WOMED) today. The company, headquartered in St. Gangloff, Thuringia, is a manufacturer of X-ray devices for the treatment of superficial skin tumors and joint diseases. WOMED has approximately 15 employees and anticipates sales of almost EUR 3 million in the current fiscal year. Aside from existing revenue from WOMED, additional sales and profits are expected through the expansion of the product portfolio. This includes the launch of a device for intraoperative radiotherapy. The acquisition can be financed from cash on hand and should be completed by 1/1/2018.
"WOMED devices have been successfully used in X-ray stimulation therapy and orthovoltage therapy around the world for decades. They are aimed at target groups that are similar to the users of tumor radiation devices from BEBIG and are an outstanding addition to our product portfolio," explains Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG GmbH and a member of the Executive Board of Eckert & Ziegler AG. We are happy to welcome the entire WOMED team and are particularly pleased that the founder and Managing Director, Andreas Wolf, will remain in management."
"Eckert & Ziegler BEBIG, which has an outstanding reputation in the industry and is internationally positioned, is the ideal partner for us," adds Andreas Wolf, founder and Managing Director of WOMED. "We are confident that our recently approved ioRT-50 X-ray therapy system for the treatment of tumor diseases will benefit from BEBIG's denser sales and service networks and we are looking forward to continuing together on the path of growth."
X-ray therapy is a radiation therapy treatment method that is used not only for the treatment of cancerous diseases. It has traditionally occupied a solid position in the therapy of benign diseases, primarily inflammatory and degenerative diseases such as arthritis, polyarthritis, and tennis elbow.
About Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) employs approximately 770 people and is one of the world's largest providers of isotope technology components for radiation therapy and nuclear medicine.Contributing to saving lives.About Eckert & Ziegler BEBIG Eckert & Ziegler BEBIG is one of the world's leading providers of brachytherapy products. Brachytherapy is a form of radiation therapy that irradiates tumors from a very close distance. The products include radioactive small implants for the treatment of prostate cancer (seeds) as well as tumor radiation devices (afterloader). Eckert & Ziegler BEBIG has approximately 130 employees worldwide and has been listed on Euronext since 1997.
Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, firstname.lastname@example.org, www.ezag.com
19.12.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin
Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: email@example.com Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service